These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28557813)

  • 41. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
    Diamantopoulos PT; Tsatsou K; Benopoulou O; Anastasopoulou A; Gogas H
    J Immunother; 2017; 40(6):221-223. PubMed ID: 28498142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
    Osman GA; Marra A; Iacono D; Giannelli V; Ricciardi S; Remotti D; Vecchione A; Ricci A; Palange P; Migliorino MR
    Anticancer Drugs; 2019 Aug; 30(7):e0764. PubMed ID: 30950836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma.
    Kichloo A; Albosta MS; McMahon S; Movsesian K; Wani F; Jamal SM; Aljadah M; Singh J
    J Investig Med High Impact Case Rep; 2020; 8():2324709620951339. PubMed ID: 32830561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
    Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
    Prasad V; Kaestner V
    Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR; Yoon JH; Kim HK; Kang HC
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pembrolizumab-induced type 1 diabetes.
    Maia A; Soares DM; Azevedo S; Pereira T; Amaral C
    J Oncol Pharm Pract; 2024 Sep; 30(6):1118-1121. PubMed ID: 38766907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
    Nishino M; Chambers ES; Chong CR; Ramaiya NH; Gray SW; Marcoux JP; Hatabu H; Jänne PA; Hodi FS; Awad MM
    Cancer Immunol Res; 2016 Apr; 4(4):289-93. PubMed ID: 26865455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pembrolizumab for the treatment of non-small cell lung cancer.
    Muller M; Schouten RD; De Gooijer CJ; Baas P
    Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
    Kashima J; Okuma Y; Shimizuguchi R; Chiba K
    Cancer Immunol Immunother; 2018 Jan; 67(1):61-65. PubMed ID: 28913619
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aprepitant for refractory nivolumab-induced pruritus.
    Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
    Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis.
    Uprety D; Arjyal L; Vallatharasu Y; Bista A; Wittchow RJ; Marinier DE
    Clin Lung Cancer; 2019 Sep; 20(5):e552-e554. PubMed ID: 31285178
    [No Abstract]   [Full Text] [Related]  

  • 55. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
    Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
    Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review.
    Abdel-Rahman O
    Immunotherapy; 2016 Dec; 8(12):1383-1391. PubMed ID: 27892744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
    Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L
    J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
    Aguiar PN; De Mello RA; Hall P; Tadokoro H; Lima Lopes G
    Immunotherapy; 2017 May; 9(6):499-506. PubMed ID: 28472902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
    Shirali AC; Perazella MA; Gettinger S
    Am J Kidney Dis; 2016 Aug; 68(2):287-291. PubMed ID: 27113507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature.
    Gemelli M; Carbone M; Abbate MI; Mancin M; Zucchini N; Colonese F; Invernizzi P; Bidoli P; Cortinovis D
    Immunotherapy; 2022 Mar; 14(4):175-181. PubMed ID: 34873918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.